Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Tirzepatide Use in Germany: Database Study

An early German utilization study described who started tirzepatide and recorded dose patterns, without testing effectiveness or a preferred dose.

Why we wrote this. Utilization data are easily mistaken for dose-effect evidence. This readout explains what the German database can describe and what it cannot establish.

In this article (5 sections)
  1. Most initiators had prior injectable diabetes treatment
  2. The dose pattern changed during follow-up
  3. The study did not measure effectiveness
  4. Funding and data-source context matter
  5. What this study can tell us

A 2026 German database study described who started tirzepatide for type 2 diabetes and how treatment was recorded during its early market use. Most people had previously received insulin, a GLP-1 receptor agonist or both. Among 458 people with at least six months of follow-up and uninterrupted use, 5.0 mg was the most common recorded dose at month six[1]. This was a descriptive utilization study, not a test of efficacy or a dosing recommendation.

Researchers used the CompuGroup Medical Healthcare Database. Cohort 1 started treatment from December 2023 through March 2024, while cohort 2 started from July through September 2024. The analysis reported baseline conditions, earlier diabetes therapy and prescribing patterns. It did not compare tirzepatide with another medicine or measure a causal treatment effect.

Most initiators had prior injectable diabetes treatment

The mean age was 59 years in cohort 1 and 60 years in cohort 2, with a standard deviation of 12 years in each. About 54% were male. Hypertension and dyslipidemia were common recorded comorbidities[2]. These data describe people seen in participating German office practices and may not represent everyone with type 2 diabetes.

Prior insulin or GLP-1 receptor agonist treatment was recorded for 72.1% of cohort 1 and 59.6% of cohort 2[1]. That pattern suggests tirzepatide was often introduced after other injectable treatment during the study period. It does not prove that those medicines failed, because the database summary does not give a patient-level reason for every change.

The lower proportion in the later cohort may reflect changing access, clinician familiarity or patient selection as use expanded. Those explanations are hypotheses. A descriptive database can show that the cohorts differed, but it cannot determine why the difference emerged without additional prescribing and patient information.

The dose pattern changed during follow-up

Among the uninterrupted-use subgroup, 71.2% started at 2.5 mg. Use of higher recorded doses increased over time. At six months, 35.9% received 5.0 mg and 18.6% received 10.0 mg[2]. These are observed prescribing frequencies in a selected subgroup, not evidence that one dose is best for a particular person.

The subgroup definition matters. It included 458 members of cohort 1 who had at least six months of data and uninterrupted tirzepatide use. People who stopped, had gaps, left the database or lacked sufficient follow-up were not represented in that month-six pattern. Restricting the analysis this way can make persistence look different from what would be seen among all starters.

Prescription records also do not prove that a medicine was dispensed or taken exactly as recorded. A dose may remain unchanged because of response, tolerability, supply, patient preference or clinical caution. The abstract does not separate those reasons. Utilization data should therefore remain a description of care, not an instruction to escalate.

The study did not measure effectiveness

The paper's stated objective was to describe characteristics and treatment utilization. It did not report a comparison of HbA1c change, weight change, cardiovascular events or adverse events between doses. A more common dose is not necessarily a more effective dose, and a recorded escalation is not evidence of a better outcome.

The authors said the cohort characteristics were generally similar to those in the SURPASS trials and argued that this supported the relevance of trial findings to practice[1]. Similarity on selected baseline characteristics does not reproduce randomization, trial follow-up or outcome ascertainment. The German database study itself cannot confirm the benefits and harms measured in SURPASS.

Our tirzepatide research overview separates randomized efficacy evidence from routine-care utilization. That distinction is essential here: one source describes what happened in controlled trials, while this paper describes how a medicine entered German practice.

Funding and data-source context matter

The PubMed record reports that several authors were employees or shareholders of Lilly, and another author received Lilly consulting fees related to the study. A database-company employee also participated[2]. These disclosures do not invalidate the results. They are relevant when readers assess study questions, analytic choices and interpretation.

The analysis used retrospective anonymized data and therefore relied on what participating practices recorded. Diagnoses can be incomplete, care outside the database may be missing and medicine use may be misclassified. The two enrollment windows were also short and early in German adoption, so later prescribing patterns may differ.

General adverse-effect context is available in the tirzepatide safety section, but this utilization paper did not supply a comparative safety analysis. Readers should not infer that uninterrupted prescribing means no adverse effects occurred.

What this study can tell us

The useful signal is operational. During early German use, tirzepatide was commonly started in people already exposed to insulin or GLP-1 therapy, and 5.0 mg was the most prevalent recorded dose after six months among uninterrupted users. The study offers a snapshot of adoption in office-based care.

It cannot tell clinicians or patients which medicine to choose, when to increase a dose or whether a recorded pattern produced better health outcomes. Those questions require outcome studies with suitable comparators and careful control of confounding. Longer follow-up would also be needed to describe persistence beyond the initial months.

People using tirzepatide should follow the plan agreed with their prescribing clinician and discuss side effects, supply interruptions or treatment changes directly. Population prescribing patterns are not a substitute for individualized diabetes care.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Was this a tirzepatide effectiveness trial?

No. It was a retrospective descriptive study of characteristics and prescribing patterns in German office-based practice, with no randomized or active comparator.

How many people were included?

The two initiation cohorts included 1,223 and 2,300 people. A selected subgroup of 458 uninterrupted users had at least six months of follow-up.

What dose was most common at six months?

Among the uninterrupted-use subgroup, 5.0 mg was most common at month six, recorded for 35.9%. That frequency is not a personal dosing recommendation.

Did the study show that dose increases improved outcomes?

No. It described recorded dose patterns and did not compare HbA1c, weight, clinical events or adverse events across dose trajectories.

Sources

  1. [1]Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany. 2026. PMID 42928086.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch record and abstract for PMID 42928086Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars